bcx 1812 has been researched along with gs 4071 in 8 studies
| Studies (bcx 1812) | Trials (bcx 1812) | Recent Studies (post-2010) (bcx 1812) | Studies (gs 4071) | Trials (gs 4071) | Recent Studies (post-2010) (gs 4071) |
|---|---|---|---|---|---|
| 25 | 1 | 12 | 190 | 16 | 140 |
| Protein | Taxonomy | bcx 1812 (IC50) | gs 4071 (IC50) |
|---|---|---|---|
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | 1.4208 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.4952 | |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | 1.63 | |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 0.0175 | |
| Neuraminidase | Influenza A virus (A/USSR/90/1977(H1N1)) | 0.0079 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.1851 | |
| Neuraminidase | Influenza A virus (A/Memphis/1/1971(H3N2)) | 0.0039 | |
| Neuraminidase | Influenza B virus (B/Lee/1940) | 0.0085 | |
| Neuraminidase | Influenza A virus (A/udorn/1972(H3N2)) | 0.5813 | |
| Sialidase | Clostridium perfringens | 0.001 | |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | 0.015 | |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | 2.8247 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0089 | |
| Neuraminidase | Influenza A virus (A/duck/Ukraine/1/1963(H3N8)) | 0.0089 | |
| Neuraminidase | Influenza A virus (A/udorn/1972(H3N2)) | 0.0029 | |
| Substance-K receptor | Cavia porcellus (domestic guinea pig) | 0.015 | |
| Neuraminidase | Influenza A virus (A/swine/Hong Kong/127/1982(H3N2)) | 0.17 | |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | 0.0007 | |
| Neuraminidase | Influenza A virus (A/budgerigar/Hokkaido/1/1977(H4N6)) | 0.0153 | |
| Integrase | Human immunodeficiency virus 1 | 1.785 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ananth, SL; Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Elliott, AJ; Horn, LL; Hutchison, TL; Kotian, P; Laver, GW; Lin, TH; Montgomery, JA; Parker, CD | 1 |
| Colman, PM; Fernley, RT; McDonald, M; McKimm-Breshkin, JL; Smith, BJ; Varghese, JN | 1 |
| Chen, XG; Chen, YL; Hu, ZD; Liu, MC; Lü, WJ; Luan, F; Ma, WP; Zhang, XY | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Cheng, TJ; Cheng, YS; Fang, JM; Huang, WI; Tsai, KC; Tseng, YC; Wang, PC; Wang, SY; Wong, CH | 1 |
| Cheng, LP; Li, L; Pang, W; Wang, Z; Zhang, XH; Zhao, JL | 1 |
| Chen, B; Lei, Z; Liu, K; Tian, Y; Wang, J; Wang, K; Yang, F; Zhang, H; Zhang, K; Zhao, H; Zhao, X; Zhu, H | 1 |
| Bi, Y; Cheng, S; Li, C; Li, X; Lv, X; Wang, P | 1 |
8 other study(ies) available for bcx 1812 and gs 4071
| Article | Year |
|---|---|
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
Topics: Acids, Carbocyclic; Administration, Oral; Animals; Antiviral Agents; Catalytic Domain; Crystallography, X-Ray; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Mice; Models, Molecular; Neuraminidase; Orthomyxoviridae Infections; Protein Binding; Stereoisomerism; Structure-Activity Relationship | 2000 |
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Topics: Acetamides; Acids, Carbocyclic; Alphainfluenzavirus; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Pyrans; Sialic Acids; Zanamivir | 2002 |
QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network.
Topics: Enzyme Inhibitors; Linear Models; Models, Biological; Neuraminidase; Quantitative Structure-Activity Relationship | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Neuraminidase; Rabbits; Structure-Activity Relationship | 2016 |
Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
Topics: Antiviral Agents; Binding Sites; Drug Design; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Inhibitory Concentration 50; Molecular Docking Simulation; Neuraminidase; Oseltamivir; Protein Structure, Tertiary; Quantitative Structure-Activity Relationship | 2017 |
Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Microbial Sensitivity Tests; Molecular Structure; Neuraminidase; Oseltamivir; Structure-Activity Relationship; Viral Proteins | 2020 |
Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
Topics: Animals; Antiviral Agents; Cholesterol; Drug Resistance, Viral; Enzyme Inhibitors; Half-Life; Humans; Influenza A Virus, H1N1 Subtype; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Rats; Rats, Sprague-Dawley; Virus Replication; Zanamivir | 2021 |